Levagen® - 60/90 servings

Levagen® is a trademarked name for a supplement ingredient called palmitoylethanolamide (PEA). Palmitoylethanolamide is a fatty acid amide naturally produced in the body and found in various food sources, such as eggs, soybeans, and peanuts. It is believed to interact with certain receptors in the body's endocannabinoid system. 

Rick first heard about this ingredient in 2021 and has since planned to add it into the range in one way or another. As the Strom RAW Range is expanding and becoming more and more popular he decided to introduce it here, and the feedback has been phenomenal.

Serving Size: 1 capsule
Servings per Container: 90

Directions for use: Take 1 capsule daily at any point of the day to help support recovery, or 2 capsules before bed.

Ingredients: Levagen® (Palmitoylethanolamide (PEA)), E470b (Bulking agent), HPCM capsule

Suitable for vegetarians. Suitable for vegans.

Re: Quality Control
[1] Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain (2014), Journal of Neuroinflammation.
Re: Pain
[2] Palmitoylethanolamide: A Potential Alternative to Cannabidiol (2021), Journal of Dietary Supplements
[3] Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials (2023), Nutrients.
[4] Palmitoylethanolamide: A Natural Compound for Health Management (2021), International Journal of Molecular Sciences
[5] Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants—A Double-Blind Randomised Controlled Study (2024), Pharmaceuticals
[6] Efficacy of Palmitoylethanolamide (Levagen+TM) Compared to Ibuprofen for Reducing Headache Pain Severity and Duration in Healthy Adults: A Double-Blind, Parallel, Randomized Clinical Trial (2021) Scientific Research Publishing.
[7]  Activation and desensitization of TRPV1 channels in sensory neurons by the PPARa agonist palmitoylethanolamide (2013), British Journal of Pharmacology.
[8] Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study (2020), Pain Research and Management
Re: Joint Health
[9] A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis (2019), Inflammopharmacology.
Re: Cognitive Health
[10] Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over Trial (2024), Nutrients
Re: Exercise Recovery
[11] The Effect of Orally Dosed Levagen+™ (palmitoylethanolamide) on Exercise Recovery in Healthy Males—A Double-Blind, Randomized, Placebo-Controlled Study
Re: Immune Function
[12] The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis—A Double-Blind Placebo-Controlled Trial (2023), Nutrients.
[13] Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold ( 2013), International Journal of Inflammation.
[14] Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19:A Randomized Controlled Trial (September 2022), The Journal of Nutrition
[15]  The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection—A Double Blind, Randomised, Placebo-Controlled Trial (October 2023), Nutrients
Re: Sleep Management
[16] Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study (2018), CSN and Neurological disorders
[17] Palmitoylethanolamide for sleep disturbance. A double‑blind, randomised, placebo‑controlled interventional study (2021), Sleep Science and Practice.
Re: Levagen vs. Levagen+
[18] Increased Absorption of Palmitoylethanolamide Using a Novel Dispersion Technology System (LipiSperse®) (May 2020), Journal Nutraceuticals and Food Science